Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ESRRB | O95718 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007980 | 0.97 | ESR1 (0.49) | ESR1ESR2CYP19A1PTGS2THRA | |
| SCHEMBL5010234 | 0.93 | ESR1 (0.51) | ESR1ESR2CYP19A1THRATHRB | |
| SCHEMBL5007982 | 0.88 | ESR1 (0.60) | ESR1ESR2CYP19A1MEN1KMT2A | |
| SCHEMBL5007263 | 0.86 | KMT2A (0.57) | ESR1ESR2CYP19A1PTGS2THRA | |
| SCHEMBL5010212 | 0.86 | ESR1 (0.50) | ESR1ESR2CYP19A1PTGS2THRA | |
| SCHEMBL3827799 | 0.81 | ESR1 (0.70) | ESR1ESR2CYP19A1PTGS2 | |
| SCHEMBL4665812 | 0.81 | ESR1 (0.60) | ESR1ESR2CYP19A1PTGS2PPARG | |
| SCHEMBL13993292 | 0.79 | MEN1 (0.60) | ESR1ESR2CYP19A1MEN1KMT2A | |
| SCHEMBL5007788 | 0.79 | ESR1 (0.48) | ESR1ESR2CYP19A1THRATHRB | |
| SCHEMBL4674036 | 0.77 | ESR1 (0.69) | ESR1ESR2CYP19A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ESR1 4/4885ESR2 2/4885CYP19A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.